Reducing postprandial hyperglycemia with adjuvant premeal pramlintide and postmeal insulin in children with type 1 diabetes mellitus

被引:17
作者
Hassan, Krishnavathana [1 ]
Heptulla, Rubina A. [1 ]
机构
[1] Baylor Coll Med, Dept Pediat, Sect Endocrinol & Metab, Houston, TX 77030 USA
关键词
children; glucagon; postprandial hyperglycemia; pramlintide; T1DM; AMYLIN ANALOG; GLYCEMIC CONTROL; CO-SECRETION; GLUCOSE; EXCURSIONS; GLUCAGON; PLASMA; THERAPY; ACETATE; ADJUNCT;
D O I
10.1111/j.1399-5448.2008.00490.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hassan K, Heptulla RA. Reducing postprandial hyperglycemia with adjuvant premeal pramlintide and postmeal insulin in children with type 1 diabetes mellitus.Pediatric Diabetes 2009: 10: 264-268. The purpose of this study was to determine the effect of adjuvant premeal pramlintide with postmeal insulin on postprandial hyperglycemia in children with type 1 diabetes mellitus (T1DM). Eight adolescents with T1DM on intensive insulin therapy participated in an open-label, non-randomized, crossover study, comparing postprandial glucose excursions in study A (prescribed insulin regimen and given premeal) vs. study B (pramlintide + insulin). Prandial insulin dose for study B was decreased by 20% and given postmeal, while pramlintide was given just before the meal. Blood glucose (BG), glucagon, and pramlintide concentrations were measured basally and at timed intervals during a 300-min study period. Postprandial incremental BG for the duration of the study was reduced in study B vs. study A with AUC((-60 to 300 min)) (area under the curve) at 6600 +/- 2371 vs. 20 230 +/- 3126 mg/dL/min (367 +/- 132 vs. 1124 +/- 174 mmol/L/min) (p < 0.001). Glucagon concentration was suppressed for similar to 120 min following administration of 30 mu g of pramlintide and postmeal insulin (p < 0.003). No severe hypoglycemic episodes were experienced in this study. Postprandial hyperglycemia is considerably reduced in adolescents with T1DM when treated with fixed-dose premeal pramlintide, and precisely calculated postmeal insulin, without significant side effects.
引用
收藏
页码:264 / 268
页数:5
相关论文
共 30 条
[1]   Limitations of conventional methods of self-monitoring of blood glucose - Lessons learned from 3 days of continuous glucose sensing in pediatric patients with type 1 diabetes [J].
Boland, E ;
Monsod, T ;
Delucia, M ;
Brandt, CA ;
Fernando, S ;
Tamborlane, WV .
DIABETES CARE, 2001, 24 (11) :1858-1862
[2]   The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type I diabetes [J].
Fineman, MS ;
Koda, JE ;
Shen, LZ ;
Strobel, SA ;
Maggs, DG ;
Weyer, C ;
Kolterman, OG .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2002, 51 (05) :636-641
[3]   BASAL AND STIMULATED PLASMA-LEVELS OF PANCREATIC AMYLIN INDICATE ITS CO-SECRETION WITH INSULIN IN HUMANS [J].
HARTTER, E ;
SVOBODA, T ;
LUDVIK, B ;
SCHULLER, M ;
LELL, B ;
KUENBURG, E ;
BRUNNBAUER, M ;
WOLOSZCZUK, W ;
PRAGER, R .
DIABETOLOGIA, 1991, 34 (01) :52-54
[4]   The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes [J].
Heptulla, RA ;
Rodriguez, LM ;
Bomgaars, L ;
Haymond, MW .
DIABETES, 2005, 54 (04) :1100-1107
[5]   Newer therapeutic options for children with diabetes mellitus: theoretical and practical considerations [J].
Jeha, GS ;
Heptulla, RA .
PEDIATRIC DIABETES, 2006, 7 (02) :122-138
[6]  
Jones MC, 2007, AM FAM PHYSICIAN, V75, P1831
[7]   A pilot study of the continuous glucose monitoring system - Clinical decisions and glycemic control after its use in pediatric type 1 diabetic subjects [J].
Kaufman, FR ;
Gibson, LC ;
Halvorson, M ;
Carpenter, S ;
Fisher, LK ;
Pitukcheewanont, P .
DIABETES CARE, 2001, 24 (12) :2030-2034
[8]   Pramlintide for the treatment of diabetes mellitus [J].
Kleppinger, EL ;
Vivian, EM .
ANNALS OF PHARMACOTHERAPY, 2003, 37 (7-8) :1082-1089
[9]   The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM [J].
Kong, MF ;
Stubbs, TA ;
King, P ;
Macdonald, IA ;
Lambourne, JE ;
Blackshaw, PE ;
Perkins, AC ;
Tattersall, RB .
DIABETOLOGIA, 1998, 41 (05) :577-583
[10]   Pramlintide for the treatment of insulin-requiring diabetes mellitus - Rationale and review of clinical data [J].
Kruger, DF ;
Gloster, MA .
DRUGS, 2004, 64 (13) :1419-1432